“Actinogen also continues to be a major beneficiary of the Australian government’s R&D tax incentive
scheme, with a tax refund of $4.8 million received last year contributing significantly to our clinical trial
funding.
With a focus on Australian clinical trial operations in the current financial year, we expect the next
R&D tax incentive rebate in H2 CY2024 to be larger again.”
Extract from the Actinogen December 2023 Quarterly report
“Actinogen also continues to be a major beneficiary of the...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
